Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Jan;55(1):83-91.
doi: 10.1007/s11239-022-02713-6. Epub 2022 Oct 3.

Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis

Tiffany T S Ye #  1 , Qi Zhuang Siah #  1 , Benjamin Y Q Tan  2   3 , Jamie S Y Ho  4 , Nicholas L X Syn  3 , Yao Hao Teo  3 , Yao Neng Teo  3 , James W Yip  3   5 , Tiong-Cheng Yeo  3   5 , Weiqin Lin  3   5 , Raymond C C Wong  3   5 , Ping Chai  3   5 , Bernard Chan  2   3 , Vijay Kumar Sharma  2   3 , Leonard L L Yeo  2   3 , Ching-Hui Sia  6   7
Affiliations
Meta-Analysis

Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis

Tiffany T S Ye et al. J Thromb Thrombolysis. 2023 Jan.

Abstract

Hypertrophic cardiomyopathy predisposes to acute cerebrovascular events including ischaemic stroke, transient ischaemic attack and systemic thromboembolism. Atrial fibrillation confers even higher risk. We aim to report the incidence of these complications and to investigate the impact of atrial fibrillation on the ischaemic risk in patients with hypertrophic cardiomyopathy. A literature search was performed on PubMed, Scopus, Embase/Ovid and Cochrane library from inception to 20th March 2021. We compared the incidence of ischaemic strokes, transient ischaemic attack, non-specified thromboembolism events and systemic thromboembolism in hypertrophic cardiomyopathy patients with or without atrial fibrillation. Non-specified thromboembolism events in our paper referred to thromboembolic events whereby types were not specified in the studies. Meta-analysis was performed using StataSE 16 software, and heterogeneity was assessed using I2 test. A total of 713 studies were identified. Thirty-five articles with 42,570 patients were included. The pooled incidence of stroke/ transient ischaemic attack was 7.45% (95% confidence interval [CI] 5.80-9.52, p < 0.001) across 24 studies with a total of 37,643 hypertrophic cardiomyopathy patients. Atrial fibrillation significantly increased the risk of total stroke/ transient ischaemic attack (Risk Ratio 3.26, 95% CI 1.75-6.08, p < 0.001, I2 = 76.0). The incidence of stroke/ transient ischaemic attack was 9.30% (95% CI 6.64-12.87, p = 0.316) in the apical hypertrophic cardiomyopathy subgroup. Concomitant atrial fibrillation in hypertrophic cardiomyopathy increases the risk of thromboembolic events including ischaemic stroke and transient ischaemic attack. The apical subgroup shows a similar risk of acute cerebrovascular events as the overall hypertrophic cardiomyopathy population.

Keywords: Atrial fibrillation; Hypertrophic cardiomyopathy; Incidence; Ischemic stroke; Transient ischemic attack.

PubMed Disclaimer

References

    1. Kimura A (2016) Molecular genetics and pathogenesis of cardiomyopathy. J Hum Genet 61:41–50. https://doi.org/10.1038/jhg.2015.83 - DOI - PubMed
    1. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE (1995) Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of 4111 subjects in the CARDIA study. Circulation 92:785–789. https://doi.org/10.1161/01.CIR.92.4.785 - DOI - PubMed
    1. Choi YJ, Choi EK, Do HK, Jung JH, Park J, Lee E et al (2018) Temporal trends of the prevalence and incidence of atrial fibrillation and stroke among Asian patients with hypertrophic cardiomyopathy: a nationwide population-based study. Int J Cardiol 273:130–135. https://doi.org/10.1016/j.ijcard.2018.08.038 - DOI - PubMed
    1. Guttmann OP, Pavlou M, O’Mahony C, Monserrat L, Anastasakis A, Rapezzi C et al (2015) Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). Eur J Heart Fail 17:837–845. https://doi.org/10.1002/ejhf.316 - DOI - PubMed
    1. Maron BJ, Maron MS (2013) Hypertrophic cardiomyopathy. Lancet 381:242–255. https://doi.org/10.1016/S0140-6736(12)60397-3 - DOI - PubMed

MeSH terms

LinkOut - more resources